GPI 5693

Drug Profile

GPI 5693

Latest Information Update: 17 Mar 2008

Price : $50

At a glance

  • Originator MGI GP
  • Class Neuroprotectants
  • Mechanism of Action Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Cerebral ischaemia; Diabetic neuropathies; Glaucoma; Neuropathic pain; Prostate cancer

Most Recent Events

  • 25 Jul 2006 This programme is still in active development with MGI GP
  • 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP
  • 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top